Expression levels of potential ICP targets, such as HAVCR2, SIRPA, and CD209, were significantly higher in the high-risk than low-risk patient group in the current study, implying that differences in intratumoral bacteria in ovarian cancer are related to the sensitivity of patients receiving immunotherapy. The gene discussed is SIRPA; the disease is ovarian cancer.